about
Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis.Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational StudyCharacterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile.The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events.Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.Psoriasis as a human model of disease to study inflammatory atherogenesis.Pathogenesis and Epidemiology of Venous Thromboembolic Disease.Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis.Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes.Self-reported depression in psoriasis is associated with subclinical vascular diseases.IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis.Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by (18)Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.TNF-α inhibitors are associated with reduced indices of subclinical atherosclerosis in patients with psoriatic disease.Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus.Potential Immunological Links Between Psoriasis and Cardiovascular Disease.Response by Lerman et al to Letters Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study"
P50
Q33917580-AE5B443A-6037-46CB-A140-A09076BD15F8Q36157875-21CEBF5D-CCBA-400C-AC40-FE8E606C9307Q36326833-E187FBDD-F078-4483-AEAC-8FF9615CD8A8Q36514727-0B2FCA88-10F5-4F86-9F33-9E70C4374F3EQ38615718-BD5A0EAB-5592-4A6B-A5D9-4FC6FAC00F2AQ38676598-759B154C-D089-4370-8146-899E0C5E2D2CQ39160397-3D58DE6F-940E-439A-8007-D4282B205871Q40180742-E30BDA49-0303-4F0F-ADB3-4CB4E086CC82Q40209798-1BCF8600-1791-4633-BFAC-690C5EEA3382Q40571559-094D2EAB-5D3E-4BAE-8FB0-9C36C3374F67Q40609419-1F77EF9F-EDE6-4A7E-A459-80CE26F131A5Q40668150-037CEFF7-5B03-45E0-9230-69CD8223CDDDQ47735274-A06DC8EB-E23B-4703-AB96-8B19DB3D4632Q47884794-26D3CD3B-B166-47A5-86AB-2F1B7A9A26E5Q48093751-61EA595D-CAAF-469C-80CC-4E7D21D00330Q55185377-40F0305A-8E02-4923-94AF-397D3950D00FQ55270893-50E9F3C1-75F2-4D67-912D-C7781E7018BFQ87969715-4229E1A3-DE63-459F-A1FD-1BBA7E946E45
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aditya A Joshi
@nl
Aditya A Joshi
@sl
Aditya A. Joshi
@en
Aditya A. Joshi
@es
type
label
Aditya A Joshi
@nl
Aditya A Joshi
@sl
Aditya A. Joshi
@en
Aditya A. Joshi
@es
prefLabel
Aditya A Joshi
@nl
Aditya A Joshi
@sl
Aditya A. Joshi
@en
Aditya A. Joshi
@es
P106
P1153
56903545100
P31
P496
0000-0003-4842-8666